Kiromic BioPharma (formerly known as Kiromic) is a target discovery and gene editing company focusing on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. It develops an allogeneic chimeric antigen receptor (CAR) cell product candidate against cancer, a checkpoint inhibitor for solid tumors, as well as oral healthcare products. The company also offers DIAMOND AI (Kiromic Diamond Artificial Intelligence), a multi-purpose computational platform that can identify cancer immunological targets for T-Cells and B-Cells.